Kiniksa Pharmaceuticals Ltd is driven by its core values of commitment, innovation, and patient-centricity. With a strong corporate philosophy, the company aims to bring transformative therapies to patients in need. Kiniksa Pharmaceuticals Ltd focuses on developing novel, targeted drugs to address unmet medical needs in immunology and inflammation. By harnessing scientific expertise and leveraging strategic collaborations, the company aims to deliver robust solutions for patients suffering from debilitating diseases. Kiniksa Pharmaceuticals Ltd is dedicated to improving patient outcomes, enhancing quality of life, and making a positive impact on the healthcare industry through its innovative and patient-centric approach.

Kiniksa Pharmaceuticals Ltd is primarily present in the United States and focuses on the development and commercialization of innovative medicines. As a biopharmaceutical company, Kiniksa Pharmaceuticals Ltd operates in multiple states across the U.S., including its headquarters in Lexington, Massachusetts. With a mission to help patients with debilitating diseases, Kiniksa Pharmaceuticals Ltd has a strong presence within the American healthcare system, collaborating with healthcare professionals, researchers, and patients to provide targeted therapies for various medical conditions.

Kiniksa Pharmaceuticals Ltd has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in June 2018, raising approximately $202 million. In the same year, Kiniksa received approval from the U.S. Food and Drug Administration (FDA) for its first drug, ARCALYST®, to treat a rare and severe autoinflammatory disease called Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Furthermore, Kiniksa Pharmaceuticals Ltd has expanded its pipeline by advancing various product candidates across multiple therapeutic areas, including immunology and oncology. These achievements demonstrate the company's commitment to developing innovative treatments and improving patient outcomes.

Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for patients living with debilitating diseases and unmet medical needs. Founded in 2015, the company is headquartered in Hamilton, Bermuda. Kiniksa Pharmaceuticals aims to address critical unmet needs in immunology and inflammation through its pipeline of innovative therapeutics. With a strong dedication to scientific excellence, the company leverages its expertise in biological insights, translational medicine, and clinical development to advance its proprietary pipeline. Kiniksa Pharmaceuticals Ltd. is committed to improving the lives of patients and delivering valuable solutions to the healthcare industry.

Some of the main competitors of Kiniksa Pharmaceuticals Ltd in the market include AbbVie Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Bristol-Myers Squibb Company.

Kiniksa Pharmaceuticals Ltd is primarily active in the biotechnology and pharmaceutical industries.

The business model of Kiniksa Pharmaceuticals Ltd focuses on developing and commercializing novel therapies for patients with debilitating diseases and unmet medical needs. Kiniksa Pharmaceuticals is dedicated to identifying and targeting key pathways involved in diseases to create innovative treatments. By utilizing its expertise in biology and immunology, the company aims to bring effective and differentiated therapies to market. Through research, clinical development, and strategic partnerships, Kiniksa Pharmaceuticals aims to improve the lives of patients and provide long-term value for its stakeholders.

Коефициентът на цена спрямо печалбата (КЦП) на Kiniksa Pharmaceuticals е -125,47.

Коефициентът на цена към оборот (KUV) на Kiniksa Pharmaceuticals е 4,17.

AlleAktien качественият резултат за Kiniksa Pharmaceuticals е 1/10.

очаквана Kiniksa Pharmaceuticals оборотът е 430,02 млн. USD.

очаквана Kiniksa Pharmaceuticals печалба е -14,29 млн. USD.

Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on the development of therapies for serious diseases. Headquartered in Hamilton, Bermuda, the company has offices in the United States and Switzerland. The company consists of two main business segments. Firstly, Kiniksa Operations, which is responsible for the development and commercialization of therapies for patients with immune-mediated diseases. Secondly, the subsidiary VIBATIV, an antibiotic for adult patients with complicated skin and soft tissue infections. Kiniksa is currently developing a range of drugs that can be used for the treatment of various diseases, including autoinflammatory syndromes, autoimmune diseases, cancer, and pain therapy. The main product of Kiniksa is Rilonacept, a human Fc-fusion protein used for the treatment of fever in patients with cryopyrin-associated periodic syndromes (CAPS). In clinical trials, Rilonacept has proven to be an effective and safe medication. The company also has other drugs in the pipeline, including KPL-716, a monoclonal antibody developed for the treatment of Prurigo nodularis, a severe chronic itching disease. The drug is currently in phase III of clinical development. Kiniksa is also working on the development of drugs for the treatment of certain types of cancer and autoinflammatory diseases such as Still's syndrome and macrophage activation syndrome. Kiniksa's products aim to slow the progression of the disease and provide patients with a higher quality of life. In order to continue this innovative research and development, Kiniksa has also entered into strategic partnerships with other companies and institutions. Partners include MedImmune, a division of AstraZeneca, and Yale University. Overall, Kiniksa aims to improve the quality of life for patients with serious diseases by developing innovative therapies and medications. The company conducts rigorous research and development, collaborates closely with partners, and is committed to the highest standards of patient safety and efficacy of its products. Through innovative therapeutic approaches and partnerships with leading academic institutions in the global market, Kiniksa has earned a reputation for the highest medical standards and excellent patient care. Thanks to differentiated therapy approaches and flexibility towards new insights and advancements in techniques and sciences, Kiniksa is always on the right side of the future and developments, thus exposed to strong growth potential.

Kiniksa Pharmaceuticals разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Kiniksa Pharmaceuticals в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Kiniksa Pharmaceuticals е BMG5269C1010.

WKN на Kiniksa Pharmaceuticals е A2JMVJ.

Тикерът на Kiniksa Pharmaceuticals е KNSA.

През последните 12 месеца Kiniksa Pharmaceuticals изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Kiniksa Pharmaceuticals да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Kiniksa Pharmaceuticals в момента е .

Kiniksa Pharmaceuticals изплаща дивидент на тримесечие. Той се разпределя в месеците .

Kiniksa Pharmaceuticals платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Kiniksa Pharmaceuticals се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Kiniksa Pharmaceuticals на 8.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 8.09.2024 г..

Последното дивидентно плащане беше извършено на 8.09.2024 г..

През година 2023 Kiniksa Pharmaceuticals изплати 0 USD под формата на дивиденти.

Дивидентите от Kiniksa Pharmaceuticals се изплащат в USD.